PedAM
Pediatric Disease Annotations & Medicines
| Disease | allergic asthma |
| Phenotype | C0004096|asthma |
| Sentences | 15 |
| PubMedID- 20883456 | Previously, we reported that 3 years of sq-standardized hdm subcutaneous immunotherapy (scit) was generally well tolerated and partly replaced the need for ics treatment to control asthma in adults with hdm-allergic asthma; hdm scit had a steroid-sparing effect (12). |
| PubMedID- 22525394 | Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review. |
| PubMedID- 21354028 | Objectives: to determine whether treatment with montelukast would improve asthma disease control in patients with mild allergic asthma during an experimentally induced rhinovirus infection. |
| PubMedID- 26385707 | Mon is a potent, selective cysteinyl leukotriene 1 (cyslt1) receptor antagonist [16] and was introduced into the market after successful clinical evaluation in patients with aspirin-sensitive asthma, nocturnal exacerbation of asthma, and allergic asthma [17]. |
| PubMedID- 25531229 | Conclusions: the presented mouse model for cat allergen-induced asthma exhibits hallmarks of chronic allergic asthma, like airway hyperresponsiveness, a mixed neutrophilic/eosinophilic infiltration in bronchoalveolar lavage, expression of il-17a and signs of remodelling in lung tissue. |
| PubMedID- 25886760 | Mon was developed as a cysteinyl leukotriene (cys-lt)-1 receptor antagonist [14] and was introduced into the market after successful clinical evaluation in patients with aspirin-sensitive asthma, nocturnal exacerbation of asthma, and allergic asthma [15]. |
| PubMedID- 26557252 | Improved asthma control in patients with severe, persistent allergic asthma after 12 months of nightly temperature-controlled laminar airflow: an observational study with retrospective comparisons. |
| PubMedID- 23110404 | Montelukast was developed as a cysteinyl leukotriene (cys-lt)-1 receptor antagonist [20] and was introduced into the market after successful clinical evaluation in patients with aspirin-sensitive asthma, nocturnal exacerbation of asthma, and allergic asthma [21]. |
| PubMedID- 22277052 | We evaluated the effect of omalizumab on asthma control in patients with persistent allergic asthma inadequately controlled with nhlbi step 4 or above asthma therapy. |
| PubMedID- 26346739 | Children are predominantly affected by allergic (extrinsic) asthma, while roughly 50% of adults have allergic asthma. |
| PubMedID- 20384875 | To elucidate the kinetics and the regulation of scd14 concentrations in bal in asthma, 18 patients with allergic asthma underwent segmental allergen challenge at different time points (10 min, 18, 42 and 162 h). |
| PubMedID- 23168918 | Conclusions: dermatophagoides pteronyssinus-induced early- and late-phase asthmatic response in patients with allergic asthma was found to be accompanied by an increased percentage of peripheral blood th17 cells and elevated serum il-17 levels as well as altered neutrophil functions. |
| PubMedID- 24349469 | Because we were intrigued by the conundrum that isocyanate-induced asthma has many features of allergic asthma, both in humans and in mouse models, and yet does not appear to depend on the presence of (humoral) ige antibodies in our model, we set out to investigate the role, if any, of b-lymphocytes in our mouse model. |
| PubMedID- 26430389 | It is currently hypothesized that the use of blood eosinophils as biomarkers could help to personalize asthma management in patients with severe allergic asthma. |
| PubMedID- 23029210 | Montelukast was developed as a cysteinyl leukotriene (cys-lt)-1 receptor antagonist [20]: after the clinical responses in patients with aspirin-sensitive asthma, nocturnal exacerbations of asthma and allergic asthma, montelukast was successfully introduced into the market [21]. |
Page: 1